Olmesartán/Hidroclorotiazida Teva (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartán/Hidroclorotiazida Teva, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with a thiazide diuretic, and is intended for adult patients. GNH USA supplies Olmesartán/Hidroclorotiazida Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartán/Hidroclorotiazida Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan/hydrochlorothiazide is used in the management of high blood pressure through combined renin‑angiotensin blockade and diuresis. - Hypertension: provides additive blood‑pressure reduction when monotherapy is insufficient. - Edema associated with hypertension: enhances fluid excretion to reduce swelling. - Cardiovascular risk reduction: contributes to lower risk of stroke and myocardial infarction in patients with hypertension. - Resistant hypertension: offers an additional therapeutic option when other regimens fail.

Both components are generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: mild to moderate light‑headedness, especially after the first doses. - Headache: transient headache that often resolves with continued therapy. - Fatigue: feeling of tiredness without a clear cause. - Electrolyte imbalance: mild reductions in potassium or sodium levels. - Increased urination: due to the diuretic effect of hydrochlorothiazide.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat requiring urgent care. - Severe electrolyte disturbances: marked hypokalemia or hyponatremia. - Acute kidney injury: sudden decline in renal function, particularly in patients with pre‑existing kidney disease. - Liver injury: rare cases of hepatitis or jaundice. - Severe hypotension: excessive drop in blood pressure leading to fainting or shock.

Before initiating therapy, consider the following precautions: - Renal function: assess baseline kidney function and monitor periodically. - Electrolytes: check serum potassium and sodium levels before and during treatment. - Diabetes: monitor blood glucose as thiazides may affect glycemic control. - Gout: be aware of potential increase in serum uric acid. - Pregnancy and lactation: avoid use unless clearly needed; discuss risks with a healthcare professional. - Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Olmesartan/hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid): - Aliskiren: concurrent use can increase risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - NSAIDs: can blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Lithium: thiazides can raise lithium levels, requiring serum monitoring. - Antidiabetic agents: thiazides may reduce glucose control, necessitating dose adjustments. - ACE inhibitors or other ARBs: combined use increases risk of hyperkalemia and renal dysfunction.